PeM: First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal Mesothelioma (clinicaltrials.gov) - Oct 24, 2026 - P2 | N=19 | Not yet recruiting | Sponsor: Fudan University
New P2 trial • Mesothelioma • Oncology • Peritoneal Mesothelioma • Solid Tumor
|